Oncovista Innovative Therapies Inc (OVIT) Return on Equity ROE from the third quarter 2015 to third quarter 2014 and annually, average high and low, overall ranking from Sep 30 2015 to Sep 30 2014 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Oncovista Innovative Therapies, Inc  (OVIT)

Oncovista Innovative Therapies Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Oncovista Innovative Therapies Inc in the third quarter 2015?
Due to the lack of equity, it was not possible to calculate Oncovista Innovative Therapies, Inc's return on equity (ROE) in its third quarter 2015

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2015)
III. Quarter		 (Jun 30 2015)
II. Quarter		 (Mar 31 2015)
I. Quarter		 (Dec 31 2014)
IV. Quarter		 (Sep 30 2014)
III. Quarter
Y / Y Equity Change - - - - -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -3 -3 -3 -3 -1
Return On Equity (TTM) - - - - -
OVIT's Total Ranking # # # # #
Equity (TTM) in Millions -7 -7 -6 -6 -4
Seq. Equity Change - - - - -
Seq. Net Income Change - - - - -

Back to OVIT Management Effectiveness >> OVIT's 5 Years Annual ROE >> Compare OVIT ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry #
Sector #
Overall #

Return On Equity Statistics
High Average Low
0 %
0 %
0 %
 





OVIT Annual Return On Equity (Dec 31 2014)
2014		 (Dec 31 2013)
2013		 (Dec 31 2012)
2012		 (Dec 31 2011)
2011
Total Equity in Millions -6 -3 -2 0 0
Y / Y Equity Change - - - - -
Net Income in Millions -3 -1 -2 -2 0
Y / Y Net Income Change - - - - -
Return On Equity - - - - -

Back to OVIT Management Effectiveness >> OVIT's 5 Years Annual ROE >> Compare OVIT ROE to its Competitors




More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
OVIT's' Return on Equity at Yahoo Finance
OVIT's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for OVIT's Competitors
Subscribers only: Roe for Oncovista Innovative Therapies Inc's Suppliers
Subscribers only: Return On Equity for OVIT's Customers




Companies with similar Return On Equity at Sep 30 2015, within Healthcare Sector ROE
Fennec Pharmaceuticals Inc   142.18 %
Adm Tronics Unlimited Inc   137.68 %
Fonar Corporation  107.77 %
Lifevantage Corp  101.10 %
Gilead Sciences Inc   99.33 %
Radnet Inc   88.50 %
Abbvie Inc   83.55 %
Travere Therapeutics Inc   63.29 %
Star Equity Holdings Inc   59.89 %
Viskase Holdings inc   58.89 %
United Therapeutics Corporation  56.69 %
Mettler toledo International Inc   53.40 %
Lumos Pharma Inc   49.69 %
Abiomed Inc   45.51 %
Vaso Corporation  44.99 %
Corbus Pharmaceuticals Holdings Inc   44.33 %
Catalent Inc   44.18 %
3m Company  37.97 %
Enanta Pharmaceuticals Inc  37.74 %
National Healthcare Corp  37.41 %
Pacific Health Care Organization Inc  36.99 %
China Biologic Products Holdings Inc   36.14 %
Zoetis Inc   34.92 %
Encompass Health Corporation  34.74 %
Lannett Company Inc  33.45 %
Teligent Inc   32.10 %
Biogen Inc   32.05 %
Akorn Inc  30.10 %
Illumina Inc   29.80 %
Vanda Pharmaceuticals Inc   29.33 %

Date modified: 2026-09-08T15:08:01+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.